nodes	percent_of_prediction	percent_of_DWPC	metapath
Pergolide—KCNH2—Sunitinib—pancreatic cancer	0.0587	0.326	CbGbCtD
Pergolide—CYP2D6—Tamoxifen—pancreatic cancer	0.0247	0.137	CbGbCtD
Pergolide—CYP2D6—Erlotinib—pancreatic cancer	0.021	0.117	CbGbCtD
Pergolide—CYP3A4—Tamoxifen—pancreatic cancer	0.0157	0.0871	CbGbCtD
Pergolide—CYP3A4—Erlotinib—pancreatic cancer	0.0133	0.0741	CbGbCtD
Pergolide—CYP3A4—Irinotecan—pancreatic cancer	0.012	0.0669	CbGbCtD
Pergolide—CYP2D6—Doxorubicin—pancreatic cancer	0.0103	0.0575	CbGbCtD
Pergolide—CYP3A4—Docetaxel—pancreatic cancer	0.00882	0.049	CbGbCtD
Pergolide—CYP3A4—Sunitinib—pancreatic cancer	0.00878	0.0488	CbGbCtD
Pergolide—CYP3A4—Doxorubicin—pancreatic cancer	0.00658	0.0365	CbGbCtD
Pergolide—Feeling abnormal—Gemcitabine—pancreatic cancer	0.000255	0.000498	CcSEcCtD
Pergolide—Orthostatic hypotension—Doxorubicin—pancreatic cancer	0.000254	0.000497	CcSEcCtD
Pergolide—Hypokalaemia—Doxorubicin—pancreatic cancer	0.000253	0.000495	CcSEcCtD
Pergolide—Angina pectoris—Epirubicin—pancreatic cancer	0.000253	0.000495	CcSEcCtD
Pergolide—Abdominal pain—Irinotecan—pancreatic cancer	0.000251	0.00049	CcSEcCtD
Pergolide—Body temperature increased—Irinotecan—pancreatic cancer	0.000251	0.00049	CcSEcCtD
Pergolide—Feeling abnormal—Fluorouracil—pancreatic cancer	0.00025	0.000489	CcSEcCtD
Pergolide—Bronchitis—Epirubicin—pancreatic cancer	0.00025	0.000489	CcSEcCtD
Pergolide—Anaemia—Docetaxel—pancreatic cancer	0.000248	0.000485	CcSEcCtD
Pergolide—Gastritis—Doxorubicin—pancreatic cancer	0.000246	0.000482	CcSEcCtD
Pergolide—Vomiting—Sunitinib—pancreatic cancer	0.000245	0.000479	CcSEcCtD
Pergolide—Body temperature increased—Gemcitabine—pancreatic cancer	0.000244	0.000477	CcSEcCtD
Pergolide—Dysuria—Epirubicin—pancreatic cancer	0.000243	0.000475	CcSEcCtD
Pergolide—Rash—Sunitinib—pancreatic cancer	0.000243	0.000475	CcSEcCtD
Pergolide—Dermatitis—Sunitinib—pancreatic cancer	0.000242	0.000474	CcSEcCtD
Pergolide—Abdominal distension—Doxorubicin—pancreatic cancer	0.000242	0.000474	CcSEcCtD
Pergolide—Headache—Sunitinib—pancreatic cancer	0.000241	0.000472	CcSEcCtD
Pergolide—Syncope—Docetaxel—pancreatic cancer	0.000241	0.000471	CcSEcCtD
Pergolide—Asthma—Doxorubicin—pancreatic cancer	0.000241	0.00047	CcSEcCtD
Pergolide—Dysphagia—Doxorubicin—pancreatic cancer	0.000241	0.00047	CcSEcCtD
Pergolide—Influenza—Doxorubicin—pancreatic cancer	0.000241	0.00047	CcSEcCtD
Pergolide—Leukopenia—Docetaxel—pancreatic cancer	0.00024	0.00047	CcSEcCtD
Pergolide—Pollakiuria—Epirubicin—pancreatic cancer	0.00024	0.00047	CcSEcCtD
Pergolide—Body temperature increased—Fluorouracil—pancreatic cancer	0.00024	0.000469	CcSEcCtD
Pergolide—Eosinophilia—Doxorubicin—pancreatic cancer	0.000238	0.000466	CcSEcCtD
Pergolide—Palpitations—Docetaxel—pancreatic cancer	0.000237	0.000464	CcSEcCtD
Pergolide—Weight increased—Epirubicin—pancreatic cancer	0.000237	0.000463	CcSEcCtD
Pergolide—Loss of consciousness—Docetaxel—pancreatic cancer	0.000236	0.000462	CcSEcCtD
Pergolide—Pancreatitis—Doxorubicin—pancreatic cancer	0.000236	0.000461	CcSEcCtD
Pergolide—Weight decreased—Epirubicin—pancreatic cancer	0.000235	0.00046	CcSEcCtD
Pergolide—Hyperglycaemia—Epirubicin—pancreatic cancer	0.000235	0.000459	CcSEcCtD
Pergolide—Cough—Docetaxel—pancreatic cancer	0.000234	0.000458	CcSEcCtD
Pergolide—Angina pectoris—Doxorubicin—pancreatic cancer	0.000234	0.000458	CcSEcCtD
Pergolide—Pneumonia—Epirubicin—pancreatic cancer	0.000233	0.000456	CcSEcCtD
Pergolide—Convulsion—Docetaxel—pancreatic cancer	0.000233	0.000455	CcSEcCtD
Pergolide—Hypertension—Docetaxel—pancreatic cancer	0.000232	0.000453	CcSEcCtD
Pergolide—Bronchitis—Doxorubicin—pancreatic cancer	0.000231	0.000452	CcSEcCtD
Pergolide—Chest pain—Docetaxel—pancreatic cancer	0.000229	0.000447	CcSEcCtD
Pergolide—Arthralgia—Docetaxel—pancreatic cancer	0.000229	0.000447	CcSEcCtD
Pergolide—Myalgia—Docetaxel—pancreatic cancer	0.000229	0.000447	CcSEcCtD
Pergolide—Nausea—Sunitinib—pancreatic cancer	0.000229	0.000447	CcSEcCtD
Pergolide—Renal failure—Epirubicin—pancreatic cancer	0.000228	0.000446	CcSEcCtD
Pergolide—Asthenia—Irinotecan—pancreatic cancer	0.000227	0.000445	CcSEcCtD
Pergolide—Neuropathy peripheral—Epirubicin—pancreatic cancer	0.000227	0.000444	CcSEcCtD
Pergolide—Jaundice—Epirubicin—pancreatic cancer	0.000226	0.000442	CcSEcCtD
Pergolide—Urinary tract infection—Epirubicin—pancreatic cancer	0.000225	0.000441	CcSEcCtD
Pergolide—Conjunctivitis—Epirubicin—pancreatic cancer	0.000225	0.000441	CcSEcCtD
Pergolide—Dysuria—Doxorubicin—pancreatic cancer	0.000225	0.00044	CcSEcCtD
Pergolide—Dry mouth—Docetaxel—pancreatic cancer	0.000224	0.000437	CcSEcCtD
Pergolide—Sweating—Epirubicin—pancreatic cancer	0.000222	0.000435	CcSEcCtD
Pergolide—Pollakiuria—Doxorubicin—pancreatic cancer	0.000222	0.000435	CcSEcCtD
Pergolide—Asthenia—Gemcitabine—pancreatic cancer	0.000222	0.000433	CcSEcCtD
Pergolide—Haematuria—Epirubicin—pancreatic cancer	0.000221	0.000432	CcSEcCtD
Pergolide—Confusional state—Docetaxel—pancreatic cancer	0.000221	0.000432	CcSEcCtD
Pergolide—Oedema—Docetaxel—pancreatic cancer	0.000219	0.000429	CcSEcCtD
Pergolide—Weight increased—Doxorubicin—pancreatic cancer	0.000219	0.000428	CcSEcCtD
Pergolide—Epistaxis—Epirubicin—pancreatic cancer	0.000219	0.000428	CcSEcCtD
Pergolide—Pruritus—Gemcitabine—pancreatic cancer	0.000219	0.000427	CcSEcCtD
Pergolide—Infection—Docetaxel—pancreatic cancer	0.000218	0.000426	CcSEcCtD
Pergolide—Weight decreased—Doxorubicin—pancreatic cancer	0.000218	0.000426	CcSEcCtD
Pergolide—Sinusitis—Epirubicin—pancreatic cancer	0.000217	0.000425	CcSEcCtD
Pergolide—Hyperglycaemia—Doxorubicin—pancreatic cancer	0.000217	0.000424	CcSEcCtD
Pergolide—Diarrhoea—Irinotecan—pancreatic cancer	0.000217	0.000424	CcSEcCtD
Pergolide—Pneumonia—Doxorubicin—pancreatic cancer	0.000216	0.000422	CcSEcCtD
Pergolide—Shock—Docetaxel—pancreatic cancer	0.000216	0.000422	CcSEcCtD
Pergolide—Pruritus—Fluorouracil—pancreatic cancer	0.000215	0.00042	CcSEcCtD
Pergolide—Thrombocytopenia—Docetaxel—pancreatic cancer	0.000215	0.00042	CcSEcCtD
Pergolide—Tachycardia—Docetaxel—pancreatic cancer	0.000214	0.000418	CcSEcCtD
Pergolide—Bradycardia—Epirubicin—pancreatic cancer	0.000212	0.000414	CcSEcCtD
Pergolide—Diarrhoea—Gemcitabine—pancreatic cancer	0.000211	0.000413	CcSEcCtD
Pergolide—Renal failure—Doxorubicin—pancreatic cancer	0.000211	0.000412	CcSEcCtD
Pergolide—Neuropathy peripheral—Doxorubicin—pancreatic cancer	0.00021	0.000411	CcSEcCtD
Pergolide—Dizziness—Irinotecan—pancreatic cancer	0.00021	0.00041	CcSEcCtD
Pergolide—Jaundice—Doxorubicin—pancreatic cancer	0.000209	0.000409	CcSEcCtD
Pergolide—Anorexia—Docetaxel—pancreatic cancer	0.000209	0.000409	CcSEcCtD
Pergolide—Rhinitis—Epirubicin—pancreatic cancer	0.000209	0.000408	CcSEcCtD
Pergolide—Urinary tract infection—Doxorubicin—pancreatic cancer	0.000208	0.000408	CcSEcCtD
Pergolide—Conjunctivitis—Doxorubicin—pancreatic cancer	0.000208	0.000408	CcSEcCtD
Pergolide—Hepatitis—Epirubicin—pancreatic cancer	0.000208	0.000407	CcSEcCtD
Pergolide—Diarrhoea—Fluorouracil—pancreatic cancer	0.000208	0.000406	CcSEcCtD
Pergolide—Pharyngitis—Epirubicin—pancreatic cancer	0.000207	0.000404	CcSEcCtD
Pergolide—Sweating—Doxorubicin—pancreatic cancer	0.000206	0.000402	CcSEcCtD
Pergolide—Oedema peripheral—Epirubicin—pancreatic cancer	0.000205	0.000401	CcSEcCtD
Pergolide—Hypotension—Docetaxel—pancreatic cancer	0.000205	0.000401	CcSEcCtD
Pergolide—Haematuria—Doxorubicin—pancreatic cancer	0.000205	0.0004	CcSEcCtD
Pergolide—Epistaxis—Doxorubicin—pancreatic cancer	0.000202	0.000396	CcSEcCtD
Pergolide—Vomiting—Irinotecan—pancreatic cancer	0.000202	0.000394	CcSEcCtD
Pergolide—Sinusitis—Doxorubicin—pancreatic cancer	0.000201	0.000393	CcSEcCtD
Pergolide—Dizziness—Fluorouracil—pancreatic cancer	0.000201	0.000393	CcSEcCtD
Pergolide—Visual impairment—Epirubicin—pancreatic cancer	0.000201	0.000392	CcSEcCtD
Pergolide—Rash—Irinotecan—pancreatic cancer	0.0002	0.000391	CcSEcCtD
Pergolide—Dermatitis—Irinotecan—pancreatic cancer	0.0002	0.000391	CcSEcCtD
Pergolide—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.0002	0.00039	CcSEcCtD
Pergolide—Headache—Irinotecan—pancreatic cancer	0.000199	0.000388	CcSEcCtD
Pergolide—Insomnia—Docetaxel—pancreatic cancer	0.000198	0.000388	CcSEcCtD
Pergolide—Paraesthesia—Docetaxel—pancreatic cancer	0.000197	0.000385	CcSEcCtD
Pergolide—Vomiting—Gemcitabine—pancreatic cancer	0.000196	0.000384	CcSEcCtD
Pergolide—Bradycardia—Doxorubicin—pancreatic cancer	0.000196	0.000383	CcSEcCtD
Pergolide—Dyspnoea—Docetaxel—pancreatic cancer	0.000195	0.000382	CcSEcCtD
Pergolide—Somnolence—Docetaxel—pancreatic cancer	0.000195	0.000381	CcSEcCtD
Pergolide—Rash—Gemcitabine—pancreatic cancer	0.000195	0.000381	CcSEcCtD
Pergolide—Dermatitis—Gemcitabine—pancreatic cancer	0.000195	0.00038	CcSEcCtD
Pergolide—Eye disorder—Epirubicin—pancreatic cancer	0.000194	0.00038	CcSEcCtD
Pergolide—Tinnitus—Epirubicin—pancreatic cancer	0.000194	0.000379	CcSEcCtD
Pergolide—Headache—Gemcitabine—pancreatic cancer	0.000193	0.000378	CcSEcCtD
Pergolide—Vomiting—Fluorouracil—pancreatic cancer	0.000193	0.000378	CcSEcCtD
Pergolide—Rhinitis—Doxorubicin—pancreatic cancer	0.000193	0.000377	CcSEcCtD
Pergolide—Dyspepsia—Docetaxel—pancreatic cancer	0.000193	0.000377	CcSEcCtD
Pergolide—Hepatitis—Doxorubicin—pancreatic cancer	0.000193	0.000377	CcSEcCtD
Pergolide—Rash—Fluorouracil—pancreatic cancer	0.000191	0.000374	CcSEcCtD
Pergolide—Dermatitis—Fluorouracil—pancreatic cancer	0.000191	0.000374	CcSEcCtD
Pergolide—Pharyngitis—Doxorubicin—pancreatic cancer	0.000191	0.000374	CcSEcCtD
Pergolide—Decreased appetite—Docetaxel—pancreatic cancer	0.000191	0.000373	CcSEcCtD
Pergolide—Headache—Fluorouracil—pancreatic cancer	0.00019	0.000372	CcSEcCtD
Pergolide—Oedema peripheral—Doxorubicin—pancreatic cancer	0.00019	0.000371	CcSEcCtD
Pergolide—Nausea—Irinotecan—pancreatic cancer	0.000188	0.000368	CcSEcCtD
Pergolide—Constipation—Docetaxel—pancreatic cancer	0.000187	0.000367	CcSEcCtD
Pergolide—Pain—Docetaxel—pancreatic cancer	0.000187	0.000367	CcSEcCtD
Pergolide—Chills—Epirubicin—pancreatic cancer	0.000187	0.000365	CcSEcCtD
Pergolide—Arrhythmia—Epirubicin—pancreatic cancer	0.000186	0.000364	CcSEcCtD
Pergolide—Visual impairment—Doxorubicin—pancreatic cancer	0.000186	0.000363	CcSEcCtD
Pergolide—Alopecia—Epirubicin—pancreatic cancer	0.000184	0.00036	CcSEcCtD
Pergolide—Nausea—Gemcitabine—pancreatic cancer	0.000183	0.000359	CcSEcCtD
Pergolide—Feeling abnormal—Docetaxel—pancreatic cancer	0.000181	0.000353	CcSEcCtD
Pergolide—Nausea—Fluorouracil—pancreatic cancer	0.00018	0.000353	CcSEcCtD
Pergolide—Eye disorder—Doxorubicin—pancreatic cancer	0.00018	0.000352	CcSEcCtD
Pergolide—Tinnitus—Doxorubicin—pancreatic cancer	0.00018	0.000351	CcSEcCtD
Pergolide—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.000179	0.00035	CcSEcCtD
Pergolide—Flatulence—Epirubicin—pancreatic cancer	0.000178	0.000349	CcSEcCtD
Pergolide—Tension—Epirubicin—pancreatic cancer	0.000178	0.000348	CcSEcCtD
Pergolide—Dysgeusia—Epirubicin—pancreatic cancer	0.000177	0.000347	CcSEcCtD
Pergolide—Nervousness—Epirubicin—pancreatic cancer	0.000176	0.000344	CcSEcCtD
Pergolide—Back pain—Epirubicin—pancreatic cancer	0.000175	0.000343	CcSEcCtD
Pergolide—Body temperature increased—Docetaxel—pancreatic cancer	0.000173	0.000339	CcSEcCtD
Pergolide—Abdominal pain—Docetaxel—pancreatic cancer	0.000173	0.000339	CcSEcCtD
Pergolide—Chills—Doxorubicin—pancreatic cancer	0.000173	0.000338	CcSEcCtD
Pergolide—Arrhythmia—Doxorubicin—pancreatic cancer	0.000172	0.000336	CcSEcCtD
Pergolide—Alopecia—Doxorubicin—pancreatic cancer	0.00017	0.000333	CcSEcCtD
Pergolide—Ill-defined disorder—Epirubicin—pancreatic cancer	0.000168	0.000329	CcSEcCtD
Pergolide—Anaemia—Epirubicin—pancreatic cancer	0.000167	0.000327	CcSEcCtD
Pergolide—Agitation—Epirubicin—pancreatic cancer	0.000166	0.000326	CcSEcCtD
Pergolide—Flatulence—Doxorubicin—pancreatic cancer	0.000165	0.000323	CcSEcCtD
Pergolide—Tension—Doxorubicin—pancreatic cancer	0.000164	0.000322	CcSEcCtD
Pergolide—Dysgeusia—Doxorubicin—pancreatic cancer	0.000164	0.000321	CcSEcCtD
Pergolide—Malaise—Epirubicin—pancreatic cancer	0.000163	0.000319	CcSEcCtD
Pergolide—Nervousness—Doxorubicin—pancreatic cancer	0.000163	0.000318	CcSEcCtD
Pergolide—Vertigo—Epirubicin—pancreatic cancer	0.000163	0.000318	CcSEcCtD
Pergolide—Syncope—Epirubicin—pancreatic cancer	0.000162	0.000318	CcSEcCtD
Pergolide—Leukopenia—Epirubicin—pancreatic cancer	0.000162	0.000317	CcSEcCtD
Pergolide—Back pain—Doxorubicin—pancreatic cancer	0.000162	0.000317	CcSEcCtD
Pergolide—Palpitations—Epirubicin—pancreatic cancer	0.00016	0.000313	CcSEcCtD
Pergolide—Loss of consciousness—Epirubicin—pancreatic cancer	0.000159	0.000311	CcSEcCtD
Pergolide—Cough—Epirubicin—pancreatic cancer	0.000158	0.000309	CcSEcCtD
Pergolide—Asthenia—Docetaxel—pancreatic cancer	0.000157	0.000308	CcSEcCtD
Pergolide—Convulsion—Epirubicin—pancreatic cancer	0.000157	0.000307	CcSEcCtD
Pergolide—Hypertension—Epirubicin—pancreatic cancer	0.000156	0.000306	CcSEcCtD
Pergolide—Ill-defined disorder—Doxorubicin—pancreatic cancer	0.000156	0.000304	CcSEcCtD
Pergolide—Pruritus—Docetaxel—pancreatic cancer	0.000155	0.000303	CcSEcCtD
Pergolide—Anaemia—Doxorubicin—pancreatic cancer	0.000155	0.000303	CcSEcCtD
Pergolide—Myalgia—Epirubicin—pancreatic cancer	0.000154	0.000302	CcSEcCtD
Pergolide—Arthralgia—Epirubicin—pancreatic cancer	0.000154	0.000302	CcSEcCtD
Pergolide—Chest pain—Epirubicin—pancreatic cancer	0.000154	0.000302	CcSEcCtD
Pergolide—Agitation—Doxorubicin—pancreatic cancer	0.000154	0.000301	CcSEcCtD
Pergolide—Anxiety—Epirubicin—pancreatic cancer	0.000154	0.000301	CcSEcCtD
Pergolide—Discomfort—Epirubicin—pancreatic cancer	0.000152	0.000298	CcSEcCtD
Pergolide—Malaise—Doxorubicin—pancreatic cancer	0.000151	0.000296	CcSEcCtD
Pergolide—Dry mouth—Epirubicin—pancreatic cancer	0.000151	0.000295	CcSEcCtD
Pergolide—Vertigo—Doxorubicin—pancreatic cancer	0.000151	0.000294	CcSEcCtD
Pergolide—Syncope—Doxorubicin—pancreatic cancer	0.00015	0.000294	CcSEcCtD
Pergolide—Leukopenia—Doxorubicin—pancreatic cancer	0.00015	0.000293	CcSEcCtD
Pergolide—Diarrhoea—Docetaxel—pancreatic cancer	0.00015	0.000293	CcSEcCtD
Pergolide—Confusional state—Epirubicin—pancreatic cancer	0.000149	0.000291	CcSEcCtD
Pergolide—Palpitations—Doxorubicin—pancreatic cancer	0.000148	0.00029	CcSEcCtD
Pergolide—Oedema—Epirubicin—pancreatic cancer	0.000148	0.000289	CcSEcCtD
Pergolide—Loss of consciousness—Doxorubicin—pancreatic cancer	0.000147	0.000288	CcSEcCtD
Pergolide—Infection—Epirubicin—pancreatic cancer	0.000147	0.000287	CcSEcCtD
Pergolide—Cough—Doxorubicin—pancreatic cancer	0.000146	0.000286	CcSEcCtD
Pergolide—Shock—Epirubicin—pancreatic cancer	0.000145	0.000284	CcSEcCtD
Pergolide—Convulsion—Doxorubicin—pancreatic cancer	0.000145	0.000284	CcSEcCtD
Pergolide—Dizziness—Docetaxel—pancreatic cancer	0.000145	0.000283	CcSEcCtD
Pergolide—Thrombocytopenia—Epirubicin—pancreatic cancer	0.000145	0.000283	CcSEcCtD
Pergolide—Hypertension—Doxorubicin—pancreatic cancer	0.000145	0.000283	CcSEcCtD
Pergolide—Tachycardia—Epirubicin—pancreatic cancer	0.000144	0.000282	CcSEcCtD
Pergolide—Hyperhidrosis—Epirubicin—pancreatic cancer	0.000143	0.000279	CcSEcCtD
Pergolide—Arthralgia—Doxorubicin—pancreatic cancer	0.000143	0.000279	CcSEcCtD
Pergolide—Chest pain—Doxorubicin—pancreatic cancer	0.000143	0.000279	CcSEcCtD
Pergolide—Myalgia—Doxorubicin—pancreatic cancer	0.000143	0.000279	CcSEcCtD
Pergolide—Anxiety—Doxorubicin—pancreatic cancer	0.000142	0.000278	CcSEcCtD
Pergolide—Discomfort—Doxorubicin—pancreatic cancer	0.000141	0.000276	CcSEcCtD
Pergolide—Anorexia—Epirubicin—pancreatic cancer	0.000141	0.000276	CcSEcCtD
Pergolide—Dry mouth—Doxorubicin—pancreatic cancer	0.00014	0.000273	CcSEcCtD
Pergolide—Vomiting—Docetaxel—pancreatic cancer	0.000139	0.000273	CcSEcCtD
Pergolide—Rash—Docetaxel—pancreatic cancer	0.000138	0.00027	CcSEcCtD
Pergolide—Hypotension—Epirubicin—pancreatic cancer	0.000138	0.00027	CcSEcCtD
Pergolide—Dermatitis—Docetaxel—pancreatic cancer	0.000138	0.00027	CcSEcCtD
Pergolide—Confusional state—Doxorubicin—pancreatic cancer	0.000138	0.00027	CcSEcCtD
Pergolide—Headache—Docetaxel—pancreatic cancer	0.000137	0.000269	CcSEcCtD
Pergolide—Oedema—Doxorubicin—pancreatic cancer	0.000137	0.000267	CcSEcCtD
Pergolide—Infection—Doxorubicin—pancreatic cancer	0.000136	0.000266	CcSEcCtD
Pergolide—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	0.000135	0.000263	CcSEcCtD
Pergolide—Shock—Doxorubicin—pancreatic cancer	0.000135	0.000263	CcSEcCtD
Pergolide—Thrombocytopenia—Doxorubicin—pancreatic cancer	0.000134	0.000262	CcSEcCtD
Pergolide—Insomnia—Epirubicin—pancreatic cancer	0.000134	0.000261	CcSEcCtD
Pergolide—Tachycardia—Doxorubicin—pancreatic cancer	0.000134	0.000261	CcSEcCtD
Pergolide—Paraesthesia—Epirubicin—pancreatic cancer	0.000133	0.00026	CcSEcCtD
Pergolide—Hyperhidrosis—Doxorubicin—pancreatic cancer	0.000132	0.000259	CcSEcCtD
Pergolide—Dyspnoea—Epirubicin—pancreatic cancer	0.000132	0.000258	CcSEcCtD
Pergolide—Somnolence—Epirubicin—pancreatic cancer	0.000131	0.000257	CcSEcCtD
Pergolide—Anorexia—Doxorubicin—pancreatic cancer	0.00013	0.000255	CcSEcCtD
Pergolide—Nausea—Docetaxel—pancreatic cancer	0.00013	0.000255	CcSEcCtD
Pergolide—Dyspepsia—Epirubicin—pancreatic cancer	0.00013	0.000254	CcSEcCtD
Pergolide—Decreased appetite—Epirubicin—pancreatic cancer	0.000129	0.000251	CcSEcCtD
Pergolide—Hypotension—Doxorubicin—pancreatic cancer	0.000128	0.00025	CcSEcCtD
Pergolide—Pain—Epirubicin—pancreatic cancer	0.000126	0.000247	CcSEcCtD
Pergolide—Constipation—Epirubicin—pancreatic cancer	0.000126	0.000247	CcSEcCtD
Pergolide—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	0.000125	0.000244	CcSEcCtD
Pergolide—Insomnia—Doxorubicin—pancreatic cancer	0.000124	0.000242	CcSEcCtD
Pergolide—Paraesthesia—Doxorubicin—pancreatic cancer	0.000123	0.00024	CcSEcCtD
Pergolide—Dyspnoea—Doxorubicin—pancreatic cancer	0.000122	0.000238	CcSEcCtD
Pergolide—Feeling abnormal—Epirubicin—pancreatic cancer	0.000122	0.000238	CcSEcCtD
Pergolide—Somnolence—Doxorubicin—pancreatic cancer	0.000122	0.000238	CcSEcCtD
Pergolide—Gastrointestinal pain—Epirubicin—pancreatic cancer	0.000121	0.000236	CcSEcCtD
Pergolide—Dyspepsia—Doxorubicin—pancreatic cancer	0.00012	0.000235	CcSEcCtD
Pergolide—Decreased appetite—Doxorubicin—pancreatic cancer	0.000119	0.000233	CcSEcCtD
Pergolide—Constipation—Doxorubicin—pancreatic cancer	0.000117	0.000229	CcSEcCtD
Pergolide—Pain—Doxorubicin—pancreatic cancer	0.000117	0.000229	CcSEcCtD
Pergolide—Abdominal pain—Epirubicin—pancreatic cancer	0.000117	0.000229	CcSEcCtD
Pergolide—Body temperature increased—Epirubicin—pancreatic cancer	0.000117	0.000229	CcSEcCtD
Pergolide—Feeling abnormal—Doxorubicin—pancreatic cancer	0.000113	0.00022	CcSEcCtD
Pergolide—Gastrointestinal pain—Doxorubicin—pancreatic cancer	0.000112	0.000219	CcSEcCtD
Pergolide—Body temperature increased—Doxorubicin—pancreatic cancer	0.000108	0.000211	CcSEcCtD
Pergolide—Abdominal pain—Doxorubicin—pancreatic cancer	0.000108	0.000211	CcSEcCtD
Pergolide—Asthenia—Epirubicin—pancreatic cancer	0.000106	0.000207	CcSEcCtD
Pergolide—Pruritus—Epirubicin—pancreatic cancer	0.000105	0.000205	CcSEcCtD
Pergolide—Diarrhoea—Epirubicin—pancreatic cancer	0.000101	0.000198	CcSEcCtD
Pergolide—Asthenia—Doxorubicin—pancreatic cancer	9.81e-05	0.000192	CcSEcCtD
Pergolide—Dizziness—Epirubicin—pancreatic cancer	9.78e-05	0.000191	CcSEcCtD
Pergolide—Pruritus—Doxorubicin—pancreatic cancer	9.68e-05	0.000189	CcSEcCtD
Pergolide—Vomiting—Epirubicin—pancreatic cancer	9.4e-05	0.000184	CcSEcCtD
Pergolide—Diarrhoea—Doxorubicin—pancreatic cancer	9.36e-05	0.000183	CcSEcCtD
Pergolide—Rash—Epirubicin—pancreatic cancer	9.32e-05	0.000182	CcSEcCtD
Pergolide—Dermatitis—Epirubicin—pancreatic cancer	9.31e-05	0.000182	CcSEcCtD
Pergolide—Headache—Epirubicin—pancreatic cancer	9.26e-05	0.000181	CcSEcCtD
Pergolide—Dizziness—Doxorubicin—pancreatic cancer	9.05e-05	0.000177	CcSEcCtD
Pergolide—Nausea—Epirubicin—pancreatic cancer	8.78e-05	0.000172	CcSEcCtD
Pergolide—Vomiting—Doxorubicin—pancreatic cancer	8.7e-05	0.00017	CcSEcCtD
Pergolide—Rash—Doxorubicin—pancreatic cancer	8.63e-05	0.000169	CcSEcCtD
Pergolide—Dermatitis—Doxorubicin—pancreatic cancer	8.62e-05	0.000169	CcSEcCtD
Pergolide—Headache—Doxorubicin—pancreatic cancer	8.57e-05	0.000168	CcSEcCtD
Pergolide—Nausea—Doxorubicin—pancreatic cancer	8.13e-05	0.000159	CcSEcCtD
Pergolide—HTR1D—Signaling Pathways—KRAS—pancreatic cancer	1.08e-05	3.49e-05	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—STAT3—pancreatic cancer	1.07e-05	3.48e-05	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—STAT3—pancreatic cancer	1.07e-05	3.48e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—CTNNB1—pancreatic cancer	1.07e-05	3.48e-05	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—APOE—pancreatic cancer	1.07e-05	3.48e-05	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—MYC—pancreatic cancer	1.07e-05	3.48e-05	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—NRAS—pancreatic cancer	1.07e-05	3.47e-05	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—NRAS—pancreatic cancer	1.07e-05	3.47e-05	CbGpPWpGaD
Pergolide—ADRA1B—GPCR downstream signaling—AKT1—pancreatic cancer	1.07e-05	3.47e-05	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—TGFB1—pancreatic cancer	1.07e-05	3.47e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling by GPCR—KRAS—pancreatic cancer	1.07e-05	3.47e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—CTNNB1—pancreatic cancer	1.07e-05	3.46e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—GCG—pancreatic cancer	1.07e-05	3.46e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—PIK3CB—pancreatic cancer	1.06e-05	3.45e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—CASP3—pancreatic cancer	1.06e-05	3.44e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling by GPCR—AKT1—pancreatic cancer	1.06e-05	3.43e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling by GPCR—PIK3CA—pancreatic cancer	1.06e-05	3.43e-05	CbGpPWpGaD
Pergolide—DRD5—Signaling Pathways—AKT1—pancreatic cancer	1.06e-05	3.42e-05	CbGpPWpGaD
Pergolide—HTR1B—Signaling Pathways—KRAS—pancreatic cancer	1.06e-05	3.42e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—MMP9—pancreatic cancer	1.05e-05	3.41e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—CCND1—pancreatic cancer	1.05e-05	3.4e-05	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—EGFR—pancreatic cancer	1.05e-05	3.4e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—MMP9—pancreatic cancer	1.05e-05	3.39e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—PTEN—pancreatic cancer	1.05e-05	3.39e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—PIK3CB—pancreatic cancer	1.05e-05	3.39e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—PTEN—pancreatic cancer	1.04e-05	3.37e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—CTNNB1—pancreatic cancer	1.04e-05	3.37e-05	CbGpPWpGaD
Pergolide—DRD4—Signaling Pathways—KRAS—pancreatic cancer	1.04e-05	3.36e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—CCND1—pancreatic cancer	1.03e-05	3.35e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—PIK3CB—pancreatic cancer	1.02e-05	3.32e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—CTNNB1—pancreatic cancer	1.02e-05	3.31e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—CXCL8—pancreatic cancer	1.02e-05	3.31e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling by GPCR—AKT1—pancreatic cancer	1.02e-05	3.31e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—MMP9—pancreatic cancer	1.02e-05	3.3e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling by GPCR—AKT1—pancreatic cancer	1.02e-05	3.29e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling by GPCR—HRAS—pancreatic cancer	1.02e-05	3.29e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—PTEN—pancreatic cancer	1.01e-05	3.28e-05	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—MYC—pancreatic cancer	1.01e-05	3.28e-05	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—TGFB1—pancreatic cancer	1.01e-05	3.27e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—CXCL8—pancreatic cancer	1.01e-05	3.26e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—SRC—pancreatic cancer	1.01e-05	3.26e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—MMP9—pancreatic cancer	1e-05	3.25e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—STK11—pancreatic cancer	1e-05	3.25e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling by GPCR—HRAS—pancreatic cancer	9.99e-06	3.24e-05	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—MYC—pancreatic cancer	9.98e-06	3.23e-05	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—MYC—pancreatic cancer	9.98e-06	3.23e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—PTEN—pancreatic cancer	9.97e-06	3.23e-05	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—TGFB1—pancreatic cancer	9.96e-06	3.23e-05	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—TGFB1—pancreatic cancer	9.96e-06	3.23e-05	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—KRAS—pancreatic cancer	9.91e-06	3.21e-05	CbGpPWpGaD
Pergolide—HTR1D—Signaling Pathways—PIK3CA—pancreatic cancer	9.9e-06	3.21e-05	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—EGFR—pancreatic cancer	9.9e-06	3.21e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling by GPCR—AKT1—pancreatic cancer	9.88e-06	3.2e-05	CbGpPWpGaD
Pergolide—DRD2—GPCR downstream signaling—AKT1—pancreatic cancer	9.87e-06	3.2e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—CXCL8—pancreatic cancer	9.85e-06	3.19e-05	CbGpPWpGaD
Pergolide—ADRA2A—Metabolism—PTEN—pancreatic cancer	9.84e-06	3.19e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling by GPCR—PIK3CA—pancreatic cancer	9.83e-06	3.18e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—VEGFA—pancreatic cancer	9.79e-06	3.17e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling by GPCR—HRAS—pancreatic cancer	9.78e-06	3.17e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—CASP3—pancreatic cancer	9.78e-06	3.17e-05	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—EGFR—pancreatic cancer	9.76e-06	3.16e-05	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—EGFR—pancreatic cancer	9.76e-06	3.16e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling by GPCR—AKT1—pancreatic cancer	9.73e-06	3.15e-05	CbGpPWpGaD
Pergolide—HTR2A—GPCR downstream signaling—AKT1—pancreatic cancer	9.72e-06	3.15e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—SRC—pancreatic cancer	9.71e-06	3.15e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—STAT3—pancreatic cancer	9.7e-06	3.14e-05	CbGpPWpGaD
Pergolide—HTR1B—Signaling Pathways—PIK3CA—pancreatic cancer	9.69e-06	3.14e-05	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—PIK3CG—pancreatic cancer	9.68e-06	3.14e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—NRAS—pancreatic cancer	9.67e-06	3.13e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—SRC—pancreatic cancer	9.66e-06	3.13e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—CASP3—pancreatic cancer	9.63e-06	3.12e-05	CbGpPWpGaD
Pergolide—HTR1D—Signaling Pathways—TP53—pancreatic cancer	9.58e-06	3.1e-05	CbGpPWpGaD
Pergolide—DRD4—Signaling Pathways—PIK3CA—pancreatic cancer	9.54e-06	3.09e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—CCND1—pancreatic cancer	9.52e-06	3.09e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—PIK3CB—pancreatic cancer	9.52e-06	3.08e-05	CbGpPWpGaD
Pergolide—ADRA1A—GPCR downstream signaling—AKT1—pancreatic cancer	9.51e-06	3.08e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—VEGFA—pancreatic cancer	9.46e-06	3.06e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—CTNNB1—pancreatic cancer	9.43e-06	3.06e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—CASP3—pancreatic cancer	9.43e-06	3.05e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—VEGFA—pancreatic cancer	9.41e-06	3.05e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—SRC—pancreatic cancer	9.39e-06	3.04e-05	CbGpPWpGaD
Pergolide—HTR1B—Signaling Pathways—TP53—pancreatic cancer	9.38e-06	3.04e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—CCND1—pancreatic cancer	9.37e-06	3.04e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—STAT3—pancreatic cancer	9.36e-06	3.03e-05	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—KRAS—pancreatic cancer	9.35e-06	3.03e-05	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—PPARG—pancreatic cancer	9.35e-06	3.03e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—NRAS—pancreatic cancer	9.34e-06	3.03e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—STAT3—pancreatic cancer	9.31e-06	3.02e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—NRAS—pancreatic cancer	9.29e-06	3.01e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—CTNNB1—pancreatic cancer	9.28e-06	3.01e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—SRC—pancreatic cancer	9.25e-06	3e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—MMP9—pancreatic cancer	9.25e-06	3e-05	CbGpPWpGaD
Pergolide—DRD4—Signaling Pathways—TP53—pancreatic cancer	9.23e-06	2.99e-05	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—KRAS—pancreatic cancer	9.22e-06	2.99e-05	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—KRAS—pancreatic cancer	9.22e-06	2.99e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—PTEN—pancreatic cancer	9.19e-06	2.98e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—CCND1—pancreatic cancer	9.17e-06	2.97e-05	CbGpPWpGaD
Pergolide—HTR1D—Signaling Pathways—HRAS—pancreatic cancer	9.16e-06	2.97e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—CXCL8—pancreatic cancer	9.15e-06	2.96e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—VEGFA—pancreatic cancer	9.15e-06	2.96e-05	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—PIK3CA—pancreatic cancer	9.11e-06	2.95e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—MMP9—pancreatic cancer	9.1e-06	2.95e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling by GPCR—HRAS—pancreatic cancer	9.09e-06	2.95e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—CTNNB1—pancreatic cancer	9.09e-06	2.94e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—STAT3—pancreatic cancer	9.06e-06	2.94e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—PTEN—pancreatic cancer	9.04e-06	2.93e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—NRAS—pancreatic cancer	9.04e-06	2.93e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—MYC—pancreatic cancer	9.01e-06	2.92e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—VEGFA—pancreatic cancer	9e-06	2.92e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—TGFB1—pancreatic cancer	8.99e-06	2.91e-05	CbGpPWpGaD
Pergolide—HTR1B—Signaling Pathways—HRAS—pancreatic cancer	8.97e-06	2.91e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling by GPCR—AKT1—pancreatic cancer	8.97e-06	2.91e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—STAT3—pancreatic cancer	8.92e-06	2.89e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—MMP9—pancreatic cancer	8.91e-06	2.89e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—NRAS—pancreatic cancer	8.89e-06	2.88e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—PTEN—pancreatic cancer	8.86e-06	2.87e-05	CbGpPWpGaD
Pergolide—ADRA2A—GPCR downstream signaling—AKT1—pancreatic cancer	8.84e-06	2.86e-05	CbGpPWpGaD
Pergolide—DRD4—Signaling Pathways—HRAS—pancreatic cancer	8.83e-06	2.86e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling by GPCR—AKT1—pancreatic cancer	8.82e-06	2.86e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—EGFR—pancreatic cancer	8.81e-06	2.86e-05	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—TP53—pancreatic cancer	8.81e-06	2.85e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—CASP3—pancreatic cancer	8.76e-06	2.84e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—MYC—pancreatic cancer	8.7e-06	2.82e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—TGFB1—pancreatic cancer	8.68e-06	2.81e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—MYC—pancreatic cancer	8.65e-06	2.8e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling by GPCR—AKT1—pancreatic cancer	8.64e-06	2.8e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—TGFB1—pancreatic cancer	8.63e-06	2.8e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—TYMS—pancreatic cancer	8.63e-06	2.79e-05	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—PIK3CA—pancreatic cancer	8.59e-06	2.78e-05	CbGpPWpGaD
Pergolide—ADRA2C—Metabolism—PIK3CA—pancreatic cancer	8.55e-06	2.77e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—CCND1—pancreatic cancer	8.52e-06	2.76e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—SRC—pancreatic cancer	8.52e-06	2.76e-05	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—PIK3CD—pancreatic cancer	8.51e-06	2.76e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—EGFR—pancreatic cancer	8.51e-06	2.76e-05	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—PIK3CA—pancreatic cancer	8.47e-06	2.75e-05	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—PIK3CA—pancreatic cancer	8.47e-06	2.75e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—EGFR—pancreatic cancer	8.47e-06	2.74e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—CTNNB1—pancreatic cancer	8.44e-06	2.74e-05	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—HRAS—pancreatic cancer	8.43e-06	2.73e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—MYC—pancreatic cancer	8.42e-06	2.73e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—TGFB1—pancreatic cancer	8.4e-06	2.72e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—SRC—pancreatic cancer	8.39e-06	2.72e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—KRAS—pancreatic cancer	8.33e-06	2.7e-05	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—TP53—pancreatic cancer	8.31e-06	2.69e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—VEGFA—pancreatic cancer	8.3e-06	2.69e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—MYC—pancreatic cancer	8.28e-06	2.68e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—MMP9—pancreatic cancer	8.28e-06	2.68e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—TGFB1—pancreatic cancer	8.26e-06	2.68e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—EGFR—pancreatic cancer	8.23e-06	2.67e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—PTEN—pancreatic cancer	8.23e-06	2.67e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—STAT3—pancreatic cancer	8.22e-06	2.66e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—SRC—pancreatic cancer	8.21e-06	2.66e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—NRAS—pancreatic cancer	8.2e-06	2.66e-05	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—TP53—pancreatic cancer	8.2e-06	2.66e-05	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—TP53—pancreatic cancer	8.2e-06	2.66e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—VEGFA—pancreatic cancer	8.17e-06	2.65e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—EGFR—pancreatic cancer	8.1e-06	2.63e-05	CbGpPWpGaD
Pergolide—HTR1D—Signaling Pathways—AKT1—pancreatic cancer	8.09e-06	2.62e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—STAT3—pancreatic cancer	8.09e-06	2.62e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—NRAS—pancreatic cancer	8.07e-06	2.61e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—KRAS—pancreatic cancer	8.04e-06	2.6e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling by GPCR—AKT1—pancreatic cancer	8.03e-06	2.6e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—VEGFA—pancreatic cancer	8e-06	2.59e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—KRAS—pancreatic cancer	8e-06	2.59e-05	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—HRAS—pancreatic cancer	7.95e-06	2.57e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—STAT3—pancreatic cancer	7.92e-06	2.57e-05	CbGpPWpGaD
Pergolide—HTR1B—Signaling Pathways—AKT1—pancreatic cancer	7.92e-06	2.57e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—NRAS—pancreatic cancer	7.9e-06	2.56e-05	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—HRAS—pancreatic cancer	7.84e-06	2.54e-05	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—HRAS—pancreatic cancer	7.84e-06	2.54e-05	CbGpPWpGaD
Pergolide—DRD4—Signaling Pathways—AKT1—pancreatic cancer	7.79e-06	2.52e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—KRAS—pancreatic cancer	7.78e-06	2.52e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—KRAS—pancreatic cancer	7.66e-06	2.48e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—PIK3CA—pancreatic cancer	7.65e-06	2.48e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—MYC—pancreatic cancer	7.64e-06	2.47e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—SRC—pancreatic cancer	7.63e-06	2.47e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—TGFB1—pancreatic cancer	7.62e-06	2.47e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—MYC—pancreatic cancer	7.52e-06	2.44e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—TGFB1—pancreatic cancer	7.5e-06	2.43e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—EGFR—pancreatic cancer	7.47e-06	2.42e-05	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—AKT1—pancreatic cancer	7.44e-06	2.41e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—VEGFA—pancreatic cancer	7.43e-06	2.41e-05	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—PIK3CB—pancreatic cancer	7.42e-06	2.4e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—TP53—pancreatic cancer	7.4e-06	2.4e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—PIK3CA—pancreatic cancer	7.39e-06	2.39e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—MYC—pancreatic cancer	7.36e-06	2.38e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—STAT3—pancreatic cancer	7.36e-06	2.38e-05	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—PTGS2—pancreatic cancer	7.35e-06	2.38e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—EGFR—pancreatic cancer	7.35e-06	2.38e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—PIK3CA—pancreatic cancer	7.35e-06	2.38e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—TGFB1—pancreatic cancer	7.34e-06	2.38e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—NRAS—pancreatic cancer	7.34e-06	2.38e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—EGFR—pancreatic cancer	7.2e-06	2.33e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—PIK3CA—pancreatic cancer	7.15e-06	2.32e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—TP53—pancreatic cancer	7.14e-06	2.31e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—TP53—pancreatic cancer	7.11e-06	2.3e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—HRAS—pancreatic cancer	7.08e-06	2.29e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—KRAS—pancreatic cancer	7.06e-06	2.29e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—PIK3CA—pancreatic cancer	7.03e-06	2.28e-05	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—AKT1—pancreatic cancer	7.02e-06	2.27e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—APOE—pancreatic cancer	7.02e-06	2.27e-05	CbGpPWpGaD
Pergolide—ADRA2C—Metabolism—AKT1—pancreatic cancer	6.98e-06	2.26e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—KRAS—pancreatic cancer	6.94e-06	2.25e-05	CbGpPWpGaD
Pergolide—ADRA2A—Metabolism—PIK3CA—pancreatic cancer	6.94e-06	2.25e-05	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—AKT1—pancreatic cancer	6.92e-06	2.24e-05	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—AKT1—pancreatic cancer	6.92e-06	2.24e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—TP53—pancreatic cancer	6.91e-06	2.24e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—MYC—pancreatic cancer	6.84e-06	2.22e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—HRAS—pancreatic cancer	6.83e-06	2.21e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—TGFB1—pancreatic cancer	6.82e-06	2.21e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—TP53—pancreatic cancer	6.8e-06	2.2e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—KRAS—pancreatic cancer	6.8e-06	2.2e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—HRAS—pancreatic cancer	6.8e-06	2.2e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—EGFR—pancreatic cancer	6.69e-06	2.17e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—HRAS—pancreatic cancer	6.61e-06	2.14e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—HRAS—pancreatic cancer	6.51e-06	2.11e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—PIK3CA—pancreatic cancer	6.48e-06	2.1e-05	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—PTEN—pancreatic cancer	6.41e-06	2.08e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—PIK3CA—pancreatic cancer	6.38e-06	2.07e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	6.33e-06	2.05e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—KRAS—pancreatic cancer	6.32e-06	2.05e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—TP53—pancreatic cancer	6.27e-06	2.03e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—AKT1—pancreatic cancer	6.25e-06	2.02e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—PIK3CA—pancreatic cancer	6.25e-06	2.02e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—TP53—pancreatic cancer	6.17e-06	2e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—PPARG—pancreatic cancer	6.11e-06	1.98e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—TP53—pancreatic cancer	6.04e-06	1.96e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—AKT1—pancreatic cancer	6.03e-06	1.95e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—AKT1—pancreatic cancer	6e-06	1.94e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—HRAS—pancreatic cancer	6e-06	1.94e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—HRAS—pancreatic cancer	5.9e-06	1.91e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—AKT1—pancreatic cancer	5.84e-06	1.89e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—PIK3CA—pancreatic cancer	5.8e-06	1.88e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—HRAS—pancreatic cancer	5.78e-06	1.87e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—AKT1—pancreatic cancer	5.75e-06	1.86e-05	CbGpPWpGaD
Pergolide—ADRA2A—Metabolism—AKT1—pancreatic cancer	5.67e-06	1.84e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—TP53—pancreatic cancer	5.62e-06	1.82e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	5.57e-06	1.8e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—HRAS—pancreatic cancer	5.37e-06	1.74e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—AKT1—pancreatic cancer	5.3e-06	1.72e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—AKT1—pancreatic cancer	5.21e-06	1.69e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—AKT1—pancreatic cancer	5.1e-06	1.65e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	4.85e-06	1.57e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—PTGS2—pancreatic cancer	4.81e-06	1.56e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—AKT1—pancreatic cancer	4.74e-06	1.54e-05	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—PIK3CA—pancreatic cancer	4.52e-06	1.47e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—PTEN—pancreatic cancer	4.19e-06	1.36e-05	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—AKT1—pancreatic cancer	3.7e-06	1.2e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	2.96e-06	9.58e-06	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—AKT1—pancreatic cancer	2.42e-06	7.83e-06	CbGpPWpGaD
